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Smoothelin-B Deficiency Results in Reduced Arterial
Contractility, Hypertension, and Cardiac Hypertrophy
in Mice
Sander S. Rensen, PhD; Petra M. Niessen, PhD; Jan M. van Deursen, PhD; Ben J. Janssen, PhD;
Edwin Heijman, MS; Evelien Hermeling, MS; Merlijn Meens, MS; Natascha Lie, MD;
Marion J. Gijbels, PhD; Gustav J. Strijkers, PhD; Pieter A. Doevendans, MD, PhD;
Marten H. Hofker, PhD; Jo G.R. De Mey, PhD; Guillaume J. van Eys, PhD
Background—Smoothelins are actin-binding proteins that are abundantly expressed in healthy visceral (smoothelin-A) and
vascular (smoothelin-B) smooth muscle. Their expression is strongly associated with the contractile phenotype of
smooth muscle cells. Analysis of mice lacking both smoothelins (Smtn-A/B/ mice) previously revealed a critical role
for smoothelin-A in intestinal smooth muscle contraction. Here, we report on the generation and cardiovascular
phenotype of mice lacking only smoothelin-B (Smtn-B/).
Methods and Results—Myograph studies revealed that the contractile capacity of the saphenous and femoral arteries was
strongly reduced in Smtn-B/ mice, regardless of the contractile agonist used to trigger contraction. Arteries from
Smtn-A/B/ compound mutant mice exhibited a similar contractile deficit. Smtn-B/ arteries had a normal architecture and
expressed normal levels of other smooth muscle cell–specific genes, including smooth muscle myosin heavy chain, -smooth
muscle actin, and smooth muscle-calponin. Decreased contractility of Smtn-B/ arteries was paradoxically accompanied by
increased mean arterial pressure (20 mm Hg) and concomitant cardiac hypertrophy despite normal parasympathetic and
sympathetic tone in Smtn-B/ mice. Magnetic resonance imaging experiments revealed that cardiac function was not
changed, whereas distension of the proximal aorta during the cardiac cycle was increased in Smtn-B/ mice. However,
isobaric pulse wave velocity and pulse pressure measurements indicated normal aortic distensibility.
Conclusions—Collectively, our results identify smoothelins as key determinants of arterial smooth muscle contractility and
cardiovascular performance. Studies on mutations in the Smtn gene or alterations in smoothelin levels in connection to
hypertension in humans are warranted. (Circulation. 2008;118:828-836.)
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Hypertension is a common condition in Western coun-tries, affecting 27% of the population worldwide. It is
a major risk factor for the development of life-threatening
conditions such as coronary heart disease and stroke. However,
the cause of increased blood pressure is unknown in most
patients.1 Smooth muscle contractility is one of the primary
determinants of vascular resistance, thereby contributing signif-
icantly to the maintenance of a physiological blood pressure.
Accordingly, molecular defects in the regulation or mechanics of
arterial smooth muscle contraction generally cause profound
cardiovascular phenotypes. For example, -smooth muscle actin
(-SMA) knockout mice display impaired vascular contractility
and reduced blood flow.2 Likewise, smooth muscle myosin
heavy chain (SM-MHC)-B knockouts show a significant de-
crease in maximal shortening velocity of vascular smooth
muscle,3 and SM-calponin–deficient mice have impaired mean
arterial pressure (MAP) regulation.4
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Despite the importance of smooth muscle cell (SMC) con-
traction for the cardiovascular system, the contractile process
itself is still incompletely understood. In particular, the functions
of regulatory proteins that are connected to the actin-myosin
filaments in vascular SMCs remain poorly defined.5 Candidate
thin filament regulatory proteins that have not been studied in
this respect are the smoothelins, which are -SMA–binding
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proteins specifically and abundantly expressed in contractile
SMCs.6–9 They are encoded by a single-copy gene that generates
2 major isoforms, both containing a troponin T–like domain.10
The smaller smoothelin-A isoform is expressed most promi-
nently in visceral SMCs. In contrast, the 110-kDa smoothelin-B,
which is encoded by the smoothelin-A exons plus 10 upstream
exons, is found only in vascular SMCs.11 Smoothelin-B expres-
sion is particularly high in muscular arteries, whereas expression
in elastic arteries is modest.7
In recent years, smoothelin-B has been increasingly recog-
nized as an excellent marker of the so-called contractile
phenotype of vascular SMCs. Indeed, loss of smoothelin-B
expression reliably indicates the disappearance of the con-
tractile SMC phenotype in various vascular disorders ranging
from aortic aneurysms to atherosclerosis and restenosis.9,12–16
Functional studies on smoothelins have been hampered by the
rapid downregulation of their expression in vitro and their
relative insolubility at physiological ionic concentrations.6
Therefore, despite its relevance for the characterization of the
contractile SMC phenotype, the function of smoothelin-B in
vascular SMCs has remained elusive. Recently, however, we
showed that smoothelin-A plays a crucial role in intestinal SMC
contraction in mice.17 Smtn-A/B/ mice, which lack both
smoothelin isoforms, develop fatal intestinal problems as a result
of drastically decreased intestinal SMC contractility. The severe
impact of smoothelin-A deficiency on visceral smooth muscle
contraction suggests that smoothelin-B might play an equally
important role in vascular smooth muscle. To test this hypoth-
esis, we generated mice lacking only smoothelin-B (Smtn-B/)
and investigated their cardiovascular physiology. We report that
smoothelin-B–deficient mice show reduced arterial contractility,
which is paradoxically accompanied by elevated MAP because
of increased peripheral vascular resistance.
Methods
Generation of Smtn-B/ Mice
To generate Smtn-B/ mice, we targeted exons 3 through 7 with a
neomycin gene under the control of the thymidine kinase promoter in
reverse orientation (Figure 1A). Targeting of embryonic stem cells
and germline transmission of the targeted alleles were detected by
Southern blotting and polymerase chain reaction (PCR) analysis
(Figure 1B; see the online-only Data Supplement for a list of
primers). Mice were further backcrossed at least 5 times on C57Bl/6
background before initiation of experiments. Because the mice had a
mixed background, we used littermates for experimentation. All
animal experiments were approved by the Maastricht University
animal ethics committee.
Quantitative Reverse-Transcriptase PCR
Total RNA was extracted from jejunum, hearts, or pooled aortas and
femoral arteries from Smtn-B/ and Smtn-B/ mice with Tri-
reagent (Sigma-Aldrich, Zwijndrecht, the Netherlands). Reverse
Figure 1. Targeting of the Smtn gene for the generation of mice lacking smoothelin-B. A, Schematic of the targeting strategy. Top, Structure
of the Smtn gene. Black boxes indicate smoothelin-B exons; light gray boxes, exons common to smoothelin-A and -B; and white boxes, tar-
geted exons. Middle, Smtn-B/ targeting vector containing neomycin resistance (NEO) and herpes simplex virus thymidine kinase (TK)
genes, both transcribed in the reverse direction to that of the Smtn gene, as indicated by arrows. Bottom, Structure of the targeted Smtn al-
lele and location of the probe used in Southern blot analyses after SacI digestion. The distance between the SacI sites in the wild-type (top)
and mutant (bottom) locus is shown. B, Left, Southern blot analyses of genomic DNA from wild-type and targeted ES cells after SacI diges-
tion with the probe indicated above (in A). The wild-type SacI fragment (WT) is 7.3 kb; the mutant SacI fragment (T) is 6.1 kb. Right, PCR
analyses of genomic DNA from Smtn-B/, Smtn-B/ and Smtn-B/ mice. The / and / PCR fragments are 191 and 240 bp, respec-
tively. C, Q-PCR analysis showing absent smoothelin-B expression in aorta, femoral artery, and jejunum of Smtn-B/ mice (left; n6 for
each genotype). Q-PCR experiments using primers and probes directed against the part that both smoothelins have in common revealed
upregulated expression of either smoothelin-A or an interrupted smoothelin-B transcript in blood vessels but not in jejunum (right; n6 for
each genotype). D, Cross sections of aortas of Smtn-B/ and Smtn-B/ mice were stained for smoothelin-A and -B (green; 400 magnifi-
cation). The cells between the autofluorescent elastic laminae do not stain, showing that smoothelins are not present in vascular SMCs of
Smtn-B/ mice. Right, Autofluorescence of the elastic laminae is shown in red.
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transcription was performed with the iScript cDNA synthesis kit
(Biorad, Veenendaal, the Netherlands) and 0.5 or 1 g RNA.
Expression of several transcripts was investigated by quantitative
PCR (Q-PCR) with the ABIPrism7700 System (Perkin Elmer,
Norwalk, Conn). Applied primers and probes are listed in the
supplemental table. The cyclophilin A transcript was used to nor-
malize the amount and quality of the extracted RNA. Smtn-B/
expression levels were set at 1.
Histology and Immunohistochemistry
Organs from mice 2 months and 1 year of age were fixed in 3.7%
formaldehyde in PBS, embedded in paraffin, sectioned, and stained with
hematoxylin and eosin. Samples of aorta and femoral artery were
snap-frozen and embedded in optical coherence tomography Tissue Tek
compound (Sakura, Chicago, Ill). Cryostat sections were blocked with
5% normal donkey serum (Jackson ImmunoResearch, Soham, UK) and
stained with a polyclonal antibody raised against 2 smoothelin-specific
peptides (described below) and a secondary antibody donkey–anti-
rabbit conjugated with FITC (Sigma-Aldrich, St Louis, Mo).
Polyclonal antibody generation was performed by Eurogentec (Sera-
ing, Belgium). Two rabbits were immunized with the smoothelin-B–
specific peptide KRFRAERQDNKENWL (smoothelin-B residues 52 to
66) and the peptide RQRKRDQRDKERERR, which is present in both
smoothelin-A and smoothelin-B (smoothelin-A residues 160 to 174,
smoothelin-B residues 614 to 628). Synthesized peptides (5 mg) were
conjugated to keyhole limpet hemocyanin. The rabbits received 3
booster injections with a 14-day interval. Sera were tested on different
tissues for cross-reactivity and smooth muscle specificity.
To determine the staining pattern of the extracellular matrix proteins
collagen and elastin, paraffin-embedded cross sections of arteries were
stained with Sirius Red and Lawson’s solution. To evaluate -SMA and
SM-MHC expression, sections were incubated with anti–-SMA
(DAKO, Glostrup, Denmark) or anti–SM-MHC antibody (Biomedical
Technologies, Stoughton, Mass) diluted 1:200 or 1:40, respectively.
Vascular Contractility
Contractility of the thoracic aorta (n10), saphenous artery (n4), and
femoral artery (n6) was compared between 10-week-old Smtn-B/
and Smtn-B/ littermates. For the contractility analyses of Smtn-A/B/
and Smtn-A/B/ littermates, mice 8 weeks of age were used (n7 for
thoracic aorta and femoral artery). Isolated arteries were mounted in
myograph organ baths as previously described.18 We examined reactiv-
ity in response to K (40 mmol/L), the thromboxane A2 mimetic
U-46619 (0.1 to 100 nmol/L), and the 1-adrenergic agonist phenyleph-
rine (0.1 to 30 mol/L), all obtained from Sigma-Aldrich. Contractile
forces were corrected for vessel segment length and medial thickness
and normalized to wild-type values.
Hemodynamics
Five-month-old male Smtn-B/ (n7) and Smtn-B/ (n10) mice
were instrumented with catheters as described before,19 and con-
scious MAP and heart rate (HR) were recorded for 30 to 60 minutes
on days 3 and 5 after surgery. In addition, the contribution of several
endogenous neurohumoral mechanisms to blood pressure was as-
sessed by the following pharmacological protocol. On day 3, MAP
and HR responses were recorded during intravenous injection of
phenylephrine (dose-response curve, 0.1 to 10 g/kg in the presence
of atropine [1.2 mg/kg] to block baroreflex-mediated bradycardia)
and after administration of the -blocker metoprolol (2.5 mg/kg). On
day 5, MAP and HR responses to the 1 blocker prazosin (0.1 mg/kg)
and the 2 blocker yohimbine (1 mg/kg) were recorded.
Pulse-wave velocity and pulse pressure were measured under
isoflurane anesthesia by a high-fidelity catheter-tip micromanometer
(Mikro-tip 1.4 F SPR-671, Millar Instruments, Houston, Tex) that
was inserted via the left carotid artery into the aorta of Smtn-B/
(n7) and Smtn-B/ (n5) mice.
Because of their physical condition and short lifespan, hemodynamic
parameters of Smtn-A/B/ and Smtn-A/B/ mice were measured in
6-week-old females under 1% to 2% isoflurane anesthesia via a catheter
introduced into the right carotid artery (n5 for each genotype).
Magnetic Resonance Imaging
Magnetic resonance imaging measurements were performed in
eleven 8-month-old male mice of each genotype with a 6.3-T
horizontal-bore animal scanner (Bruker BioSpin, Ettlingen, Ger-
many) and a 3-cm-diameter birdcage radiofrequency coil (Rapid
Biomedical, Rimpar, Germany). End-diastolic volume, end-systolic
volume, stroke volume, ejection fraction, and left ventricular mass
(1.05 g/cm3)20 were calculated from a semiautomatic segmentation
of the images with the FARM MRV CAAS software provided by Pie
Medical Imaging (Maastricht, the Netherlands).21
To determine the distension of the descending thoracic aorta during
the cardiac cycle, a modified fast low-angle shot sequence was used
with an in-plane navigator echo.21 The distension of the thoracic aorta
was measured manually at a fixed position for 7 Smtn-B/ and 5
Smtn-B/ mice. From these data, the relative distension as function of
time and the maximum distension were derived.
Statistical Analysis
Statistical significance was calculated by 2-tailed Student t tests or
repeated-measures 2-way ANOVA as indicated with Graphpad Prism
software (version 4.0) and SPSS software (version 15.0; SPSS Inc,
Chicago, Ill). Results were considered significantly different at values of
P0.05. Values are expressed as meanSEM. The online-only Data
Supplement provides a more detailed Methods section.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Smtn-B/ Mice Develop Normally, Expressing
Smoothelin-A but No Intact Smoothelin-B
To generate Smtn-B/ mice, we replaced Smtn exons 3
through 7 with a neomycin-resistance cassette (Figure 1A and
1B). This deletion disrupts the smoothelin-B gene while
leaving the smoothelin-A promoter intact.22 Intercrosses of
Smtn-B/ mice produced Smtn-B/ offspring at mendelian
frequency (Smtn-B/, 28%; Smtn-B/, 50%; Smtn-B/,
22%; n506), indicating that loss of smoothelin-B does not
interfere with embryonic survival. In contrast to Smtn-A/B/
mice, which die rapidly after birth,17 Smtn-B/ mice ap-
peared normal, had no gross histological abnormalities in any
organ as evaluated by an experienced animal pathologist, and
had unaltered intestinal function.17
Q-PCR analyses showed an absence of intact smoothelin-B
transcripts in the aorta, femoral artery, and jejunum of Smtn-B/
mice (Figure 1C). On the other hand, upregulation of either
smoothelin-A or an interrupted smoothelin-B transcript still
containing its 3 smoothelin-A sequence was found in Smtn-B/
blood vessels (Figure 1C). However, smoothelins were not
detectable in the aorta of Smtn-B/ mice by immunohistological
stainings with polyclonal antibodies recognizing both
smoothelin-A and smoothelin-B (Figure 1D). Thus, Smtn-B/
mice display a null mutation in vascular tissue and can be used
to delineate the role of smoothelin-B in vascular smooth muscle
function. As predicted, Smtn-B/ mice displayed normal
smoothelin expression in visceral tissues (Figure 1C).
Normal Contractile Gene Expression and Normal
Arterial Structure in Smtn-B/ Mice
To study whether levels of important contractile smooth
muscle–specific genes were altered by the loss of
smoothelin-B, we examined the expression of -SMA, SM-
MHC, and SM-calponin in arteries of 6-month-old mice by
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Q-PCR (n6 for each genotype). The expression of these
components of the SMC contractile machinery was not
significantly changed at the mRNA level (Figure 2A). In
addition, both -SMA (Figure 2B) and SM-MHC proteins
(S.S.R., unpublished data, 2007) were readily detectable in
medial SMCs of Smtn-B/ mice. Moreover, the femoral
artery and aorta of Smtn-B/ mice appeared histologically
normal and had a similar medial cross-sectional area and
vessel radius compared with Smtn-B/ mice (cross-sectional
area of aorta, 0.0860.004 versus 0.0750.004 mm2; cross-
sectional area of femoral artery, 0.01070.0005 versus
0.01010.0005 mm2; radius of aorta, 3674 versus 34910
m; radius of femoral artery, 1455 versus 1435 m for
Smtn-B/ versus Smtn-B/ mice, respectively). The staining
patterns of the extracellular matrix proteins collagen and
elastin also were normal in Smtn-B/ mice, showing regular
arrangement of elastic fibers and laminae without fragmen-
tation (Figure 2C and 2D). Hence, loss of smoothelin-B does
not affect blood vessel architecture or the expression of other
major smooth muscle contractile proteins.
Severely Compromised Arterial Contractile
Capacity in Smtn-B/ Mice
To examine the effect of smoothelin-B deficiency on vascular
smooth muscle function, we measured contractility of the
femoral artery and the saphenous artery, which contain high
amounts of smoothelin-B. We also determined contractility of
the thoracic aorta, which contains little smoothelin-B.7 Sev-
eral contractile agonists were applied to isolated vessel
segments in a myograph to assess the integrity of different
signal transduction pathways that activate SMC contraction.
Because sensitivities to the contractile stimuli did not differ
significantly between genotypes, only differences between
maximal responses are discussed. Maximal contractile re-
sponses generated by aortas of Smtn-B/ mice were attenu-
ated during stimulation with K, the thromboxane A2 mimetic
U46619, or the 1-adrenergic agonist phenylephrine, al-
though the difference with Smtn-B/ aortas was not signifi-
cant (Figure 3A). In contrast, maximal contractions produced
by both femoral and saphenous arteries of Smtn-B/ mice
were strongly and significantly decreased compared with
Figure 2. Normal contractile gene expression and arterial structure in Smtn-B/ mice. A, Expression of -SMA, SM-MHC, and SM-calponin
(SM-Calp) was measured by Q-PCR (n6 for each genotype). Levels were normalized to cyclophilin A expression, and Smtn-B/ levels were
set at 1. No significant change in expression levels was found between Smtn-B/ and Smtn-B/ mice. B, Representative immunohisto-
chemical staining of -SMA in the aorta (top; 100 magnification) and femoral artery (bottom; 200 magnification) of Smtn-B/ and Smtn-
B/ mice showing no differences between the genotypes. C, Representative images of Sirius Red staining of the aorta (top; 400 magnifica-
tion) and femoral artery (bottom; 200 magnification) of Smtn-B/ and Smtn-B/ mice showing no major differences in collagen content or
distribution. D, Representative images of Lawson’s elastin staining of the aorta (top; 400 magnification) and femoral artery (bottom; 200
magnification) of Smtn-B/ and Smtn-B/ mice showing regular elastic fibers in both genotypes.
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control mice (Figure 3B and 3C). Contractility of the femoral
artery in response to phenylephrine was reduced by 	50%.
Maximal contractile responses of the saphenous artery to all
3 stimuli were reduced by 60% to 70%.
To investigate whether lack of smoothelin-A on top of
smoothelin-B deficiency has an additional effect on vascular
smooth muscle performance, we tested the same vasoactive
compounds on arterial vessels isolated from Smtn-A/B/ mice.
Of note, Smtn-A/B/ mice had a decreased medial cross-
sectional area of the thoracic aorta and femoral artery that was
proportional to their smaller body size.17 The reduced smooth
muscle volume was corrected for in the contractility analyses.
Thoracic aortas of Smtn-A/B/ mice displayed a more pro-
nounced reduction of maximal responses to phenylephrine
(Figure 3D). Femoral arteries of Smtn-A/B/ mice showed
greatly reduced contractility regardless of the type of agonist
used to trigger contraction (Figure 3E). In general, the extent of
the reductions were comparable to those observed in Smtn-B/
vessels. Taken together, these data show that smoothelin-B is an
important determinant of muscular artery contractility.
Increased MAP and Cardiac Hypertrophy in
Smtn-B/ Mice
The physiological consequences of the reduced arterial con-
tractility in Smtn-B/ mice were analyzed by measuring
several hemodynamic parameters in conscious mice. Surpris-
ingly, basal MAP was significantly higher in Smtn-B/ mice
than in control mice (20 mm Hg; P0.01), whereas HR
was not different (Figure 4A).
In line with the elevated MAP, Smtn-B/ mice developed a
significantly higher ratio of heart weight to body weight at 8
Figure 3. Decreased vascular smooth muscle contractility in Smtn-B/ and Smtn-A/B/ mice. Maximal contractile responses to K,
phenylephrine (PHE), and U46619 of aorta (A; n10 for each genotype), femoral artery (B; n6 for each genotype), and saphenous
artery (C; n4 for each genotype) of Smtn-B/ mice were diminished (femoral artery: K, P0.03; PHE, P0.01; saphenous artery: K,
P0.01; PHE, P0.01; U46619, P0.01). Maximal contractility of the aorta (D; n7 for each genotype) and the femoral artery (E; n7
for each genotype) of Smtn-A/B/ mice was reduced to the same extent as in Smtn-B/ mice (aorta: PHE, P0.01; femoral artery:
K, P0.05; PHE, P0.01; U46619, P0.05). Active wall stress was normalized to wild-type values. *Statistically significant differences.
Figure 4. Smtn-B/ mice develop elevated blood pressure and cardiac hypertrophy. A, Smtn-B/ mice (n10) displayed elevated
MAP compared with Smtn-B/ mice (n7) (P0.01), whereas HR was comparable. B, Ratio of heart weight to body weight (HW/BW)
was increased (P0.01), whereas BW was unaltered in Smtn-B/ mice (Smtn-B/, n15; Smtn-B/, n13). C, Ventricular atrial natri-
uretic factor (ANF) and brain natriuretic peptide (BNP) levels as measured by Q-PCR were elevated in Smtn-B/ mice (P0.05,
P0.08, respectively; n11 for each genotype). Smtn-B/ levels were set at 1. *Statistically significant differences.
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months of age (Figure 4B). Morphometric analysis of the hearts
of these mice showed that both the left and right ventricular
walls were enlarged (left ventricle cross-sectional area,
13.40.1 versus 12.90.1 mm2; right ventricle cross-sectional
area, 5.40.6 versus 4.80.4 mm2 for Smtn-B/ versus Smtn-
B/ mice). The number of cardiomyocyte nuclei per 1 mm2 was
similar (79.83.0 versus 79.44.1 for Smtn-B/ versus Smtn-
B/ littermates), consistent with a hypertrophic response. To
establish whether the increased ratio of heart weight to body
weight indeed reflected cardiac hypertrophy, we measured the
expression of the cardiac hypertrophy markers atrial natriuretic
factor and brain natriuretic peptide in the hearts of 8-month-old
mice (n11 for each genotype). mRNA levels of both natriuretic
peptides were elevated in Smtn-B/ mice compared with Smtn-
B/ littermates (Figure 4C).
Increased MAP and higher ratios of heart weight to body
weight also were detected in Smtn-A/B/ mice at the young age
of only 6 weeks (MAP: 955 versus 872 mm Hg, P0.01;
ratio of heart weight to body weight: 6.80.9 versus 5.80.4
mg/g, P0.01 for Smtn-A/B/ versus Smtn-A/B/ littermates).
Collectively, these results show that smoothelin deficiency
results in elevated blood pressure, leading to cardiac
hypertrophy.
Normal Blood Pressure Control in Smtn-B/ Mice
To determine whether the increased MAP in Smtn-B/ mice
was due to alterations in endogenous blood pressure control
mechanisms, we determined MAP and HR after injection of
several autonomic nervous system blockers in conscious mice.
Smtn-B/ and Smtn-B/ mice displayed similar changes in
MAP and HR after administration of atropine or atropine plus
metoprolol (Figure 5A and 5B), indicating that cardiac parasym-
pathetic tone and sympathetic tone were comparable. In addi-
tion, the MAP response to the -adrenergic blockers prazosin
and yohimbine did not differ between Smtn-B/ and Smtn-B/
mice (Figure 5C). Thus, no difference exists in autonomic
control that may explain the different MAP between the geno-
types. In line with the myograph data, MAP responses to
intravenous bolus injections of the 1-adrenergic agonist phen-
ylephrine were lower in Smtn-B/ mice than in Smtn-B/ mice,
although the differences were not significantly different at any
dose (Figure 5D and 5E).
Normal Cardiac Function but Increased
Peripheral Vascular Resistance in Smtn-B/ Mice
The distensibility of the large arteries affects central arterial
pressure. Therefore, we first investigated whether decreased
distensibility in Smtn-B/ animals contributes to the elevated
Figure 5. Normal blood pressure control in Smtn-B/ mice. Changes in MAP (A) and HR (B) after muscarinic blockade by bolus injec-
tion of atropine followed by 1 blockade using metoprolol were not different between Smtn-B/ (n7) and Smtn-B/ mice (n10). C,
Full blockade of 1-adrenergic receptors using prazosin or 2-adrenergic receptors using yohimbine caused a similar decline in MAP in
Smtn-B/ (n7) and Smtn-B/ (n10) mice. D, Representative tracings of pressor responses to an intravenous bolus of the
1-agonist phenylephrine (PHE) in conscious unrestrained Smtn-B/ (thin line) and Smtn-B/ (thick line) mice. E, Comparison of the
average pressor responses to a dose range of PHE in Smtn-B/ (▫; n7) and Smtn-B/ (; n10) mice. Data were compared by
2-way (genotype, dose) repeated-measures ANOVA.
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MAP. We measured pulse-wave velocity and pulse pressure in
the thoracic aorta. At comparable HRs (57336 versus 56238
bpm for Smtn-B/ and Smtn-B/ animals; P0.80) and com-
parable MAPs (899 versus 861 mm Hg for Smtn-B/ and
Smtn-B/ animals; P0.45), no significant difference was
found in either pulse-wave velocity or pulse pressure (Figure
6A), demonstrating unchanged aortic distensibility in Smtn-B/
mice.
MAP is by definition the product of cardiac output and
total peripheral vascular resistance. Consequently, the ele-
vated MAP in Smtn-B/ mice might arise from increases in
either or both of these factors. We first analyzed cardiac
output by magnetic resonance imaging. Stroke volume, HR,
and cardiac output did not differ between Smtn-B/ and
Smtn-B/ littermates (Table). Because cardiac output was not
increased, the elevated MAP in Smtn-B/ mice had to be due
to increased peripheral vascular resistance. Analysis of the
distension of the aorta during the cardiac cycle by magnetic
resonance imaging (Figure 6B) revealed increased distension
in Smtn-B/ mice throughout the cardiac cycle (Figure 6C).
The maximal distension was almost 2-fold greater for Smtn-
B/ mice (P0.01; Figure 6D). The lumen diameter of the
thoracic aorta at the end-diastolic heart phase was 1.150.15
versus 1.050.17 mm for the Smtn-B/ and Smtn-B/ mice,
respectively. The increased aortic distension despite similar
aortic distensibility and comparable cardiac output implies
the presence of increased peripheral vascular resistance,
which causes elevated MAP in Smtn-B/ mice.
Discussion
The present study was instigated by our recent demonstration
that mice lacking both smoothelin isoforms display markedly
reduced intestinal smooth muscle contraction.17 In line with
this, we show here that loss of the vascular-specific
smoothelin-B protein leads to greatly diminished vascular
contractile capacity. Paradoxically, this is accompanied by
elevated MAP and cardiac hypertrophy. Because cardiac
output, autonomic nervous system activity, and large-artery
properties are not altered in smoothelin-B–deficient mice, the
increased pressure must have its origin in altered microvas-
cular properties. The data obtained in this study provide the
first evidence that smoothelin-B is essential for vascular
smooth muscle performance.
Reduced contractility of Smtn-B/ muscular arteries was
observed regardless of the signal transduction pathways
activated. Together with the binding of smoothelin-B to the
contractile filaments,23 this nonselective reduction of contrac-
tility suggests that smoothelin-B plays a role at the core of the
Figure 6. Increased aortic distension
but normal aortic distensibility in
Smtn-B/ mice. A, Pulse-wave veloc-
ity (PWV) and pulse pressure (PP)
measurements at comparable HRs
and MAPs show no difference
between Smtn-B/ (n5) and Smtn-
B/ (n7) mice, indicating normal
aortic distensibility. B, MR image of
the aorta of a Smtn-B/ mouse at the
end-diastolic heart phase. The white
line indicates the position of the lumen
diameter measurement. C, Aortic dis-
tension in Smtn-B/ mice () was
increased throughout the cardiac
cycle compared with Smtn-B/ mice
(). The beginning of the systolic heart
phase is represented by 0, the end-di-
astolic phase by 1. D, Maximal disten-
sion was almost 2-fold greater in
Smtn-B/ mice (Smtn-B/, n5;
Smtn-B/, n7). *Statistically signifi-
cant differences.
Table. Characteristics of Cardiac Function of Smtn-B/
(n11) and Smtn-B/ (n11) Mice as Measured by Magnetic
Resonance Imaging
Parameter Smtn-B/ Smtn-B/
End-diastolic volume, L 442.6 472.1
End-systolic volume, L 100.8 131.2
Ejection fraction, % 761.1 731.2*
Left ventricular mass, mg 1142.7 1014.5*
Stroke volume, L 342.0 341.1
HR, bpm 52111 5276
Cardiac output, mL/min 17.71.0 18.10.7
*P0.02.
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vascular SMC contractile machinery. The mechanism by
which smoothelin-B affects smooth muscle contraction needs
more study. The cardiovascular phenotype of other knockout
mouse models of contractile SMC proteins has been shown to be
due to downregulation of other proteins involved in SMC
contraction, upregulation of related proteins, or expression of
different alternatively spliced contractile proteins.2,3,24,25 We
have excluded the possibility that downregulation of the most
important SMC contractile genes is responsible for the pheno-
type of Smtn-B/ mice. In addition, smoothelin homologs are
not detected by database searches, making it unlikely that
upregulation of such proteins can compensate for the loss of
smoothelin function. It cannot be completely ruled out, however,
that changes in alternative splicing or organization of other
contractile proteins occur in Smtn-B/ animals.
An important determinant of the amount of contractile
force in muscle contraction is the degree of cooperativity
between multiple actomyosin cross-bridges. Cooperativity in
skeletal muscle is coordinated by tropomyosin and the tropo-
nin proteins.26 However, troponins are not expressed in
SMCs. Instead, smooth muscle tropomyosin interacts with
h-caldesmon and SM-calponin, which partly take over the
role of troponins.5 Importantly, smoothelins contain a 37–
amino acid sequence that is similar to the tail domain of
troponin T.10 In skeletal muscle, this domain not only is
required for troponin T interaction with tropomyosin but also
is involved in the activation of actomyosin ATPase.27 Thus,
smoothelins might be part of a smooth muscle tropomyosin-
troponin–like system. The diminished contractile potential of
vascular smooth muscle of Smtn-B/ mice may be due to a
lack of cooperativity of contraction, which then would
depend on a functional smoothelin-tropomyosin system.
Surprisingly, the reduced contractile capacity of smooth-
elin-B–deficient muscular arteries ex vivo was accompanied
by elevated blood pressure in Smtn-B/ mice. However,
reduced maximal vascular contractility does not necessar-
ily manifest itself in the MAP. Elevation of mean blood
pressure may occur as a result of increased cardiac output,
increased total peripheral resistance, or their combination.
The magnetic resonance imaging measurements in this
study show that cardiac output in the Smtn-B/ mice is not
changed. Therefore, the peripheral resistance of the vascula-
ture must be affected by the mutation, which is conceivable
considering the significant expression of smoothelin-B in the
smaller vessels. The increased aortic distension despite sim-
ilar cardiac output and similar aortic structure, diameter, and
distensibility in Smtn-B/ mice supports that increased resis-
tance to blood flow is brought about by the smaller down-
stream parts of the vascular tree.
It is unlikely that the increased MAP is caused by overactivity
of the autonomic nervous system because neither blockade of
muscarinic receptors nor blockade of 1- or 1/2-adrenergic
receptors revealed differences in blood pressure response and
because HR did not differ between the genotypes either. How-
ever, changes in other neurohumoral vasopressor systems that
control blood pressure, changes in arterial relaxation properties,
or differences in the total number of vessels might contribute to
the altered MAP in Smtn-B/ mice. In addition, we cannot rule
out that smoothelin deficiency might have a stimulatory effect
on arteriole contractility.
Overall, the cardiovascular phenotype of Smtn-B/ mice is
similar to that of patients with established hypertension.
They, too, have a normal cardiac output with a hypertrophic
heart, accompanied by increased peripheral resistance.28
Two other observations in this study deserve further
comment. First, we found no indications of SMC phenotype
changes such as decreased contractile gene expression or
altered cell morphology in Smtn-B/ mice. Therefore, it is
unlikely that smoothelin-B plays a role in the regulation of
SMC differentiation, as was previously suggested on the basis
of its strict contractile phenotype-specific expression.23 Sec-
ond, arterial contractility was similarly reduced in mice
lacking both smoothelins and mice lacking only
smoothelin-B, indicating that smoothelin-B is the functional
smoothelin isoform in vascular smooth muscle.
Conclusions
The data in this study show that smoothelin-B deficiency
causes a major decline in the contractile performance of
vascular smooth muscle. Instead of merely reflecting the
SMC contractile phenotype, smoothelins appear to actively
participate in the contractile process itself. Mutations in the
Smtn gene or alterations in smoothelin levels may therefore
contribute to the development of hypertension and concom-
itant cardiac hypertrophy in humans.
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CLINICAL PERSPECTIVE
The causes of essential hypertension remain largely unknown, although it is commonly accepted that vascular smooth muscle
dysfunction is a potential culprit. Improved insight into the mechanics and regulation of smooth muscle contraction may provide
additional therapeutic targets to treat pathologies such as hypertension. However, our current understanding of these 2 aspects
of smooth muscle function is limited. Here, we introduce smoothelin, a protein specifically expressed in fully differentiated,
contractile smooth muscle cells, as a crucial component of the vascular smooth muscle cell contractile apparatus. We demonstrate
for the first time that smoothelin is necessary for physiological vascular smooth muscle contraction. Smoothelin deficiency in
mice resulted in severely reduced contractile potential, particularly in smaller arteries. Paradoxically, this was accompanied by
hypertension and concomitant cardiac hypertrophy. Analyses of differently sized blood vessels indicated that the cause of the
hypertension is likely to be downstream of vessels like the saphenous artery and/or mediated by overcompensation of blood
pressure regulatory systems like the renin-angiotensin system. Recently, imatinib, a drug used in clinical practice, was shown to
specifically promote smoothelin expression in vascular smooth muscle cells. Considering the currently reported data, such an
increase in smoothelin concentration not only may indicate a more contractile phenotype of the vascular smooth muscle cell but
also may improve vascular smooth muscle contractile potential. The combination of an increased knowledge of smoothelin
function and the availability of pharmacological tools that affect smoothelin expression provides interesting opportunities to treat
pathologies originating from vascular smooth muscle cell dysfunction.
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